cancer of unknown primary
Canhelp Genomics Partners With Mirxes Singapore to Offer Tumor Origin Identification Testing
The firms will make the Canhelp-Origin tumor identification test available for patients with cancers of unknown origin in some Southeast Asian countries.
New Data Shore Up Evidence for Paired Tumor Origin, Molecular Testing in Cancer of Unknown Primary
Premium
Biotheranostics' CancerType ID can predict tumor origins for the majority of CUP patients, with reflex biomarker testing finding those eligible for targeted treatment.
The firm is building a case for clinical utility of its gene expression test for cancer of unknown primary following a successful validation study.
Genomic Profiling Aids Patients With Cancers of Unknown Primary in Trial, Though Benefit is Limited
In the CUPISCO trial, molecularly guided treatment reduced the risk of progression or death by 28 percent compared to patients receiving chemotherapy.
Gene Expression Assay Shows Ability to Guide Targeted Treatment for Patients With Occult Cancers
Premium
Patients with cancers of unknown primary had more treatment options and better outcomes when care was informed by a 90-gene expression assay.